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Surveillance	for	hepatitis	C	virus	infection	in	6	US	sites	
identified	20,285	newly	reported	cases	in	12	months	(report	
rate	69	cases/100,000	population,	range	25–108/100,000).	
Staff	reviewed	4	laboratory	reports	per	new	case.	Local	sur-
veillance data can document the effects of disease, support 
linkage to care, and help prevent secondary transmission.
H
epatitis C virus (HCV) infection is a serious public 
health problem in the United States and throughout 
the world. At least 80% of acute infections become chronic 
(1); an estimated 3.2 million persons in the United States 
alone have chronic HCV infection (2). In 2004, an HCV 
diagnosis was made in 936 of 100,000 outpatient visits 
for healthcare and in 143 of 100,000 hospital discharges 
(3). This is a chronic infection in which complications are 
manifested decades after the initial infection. Complica-
tions and costs associated with chronic HCV infection are 
anticipated to increase during 2010–2019 (4), because the 
incidence of new infections peaked from the late 1960s to 
early 1980s (5).
Although  identifying  persons  with  HCV  infection, 
including asymptomatic persons, is challenging, the ben-
efits for overall public health make it worthwhile. Infected 
persons can be referred to care (6), treated (if appropriate) 
(7), and counseled to prevent complications. The Centers 
for Disease Control and Prevention (CDC) and the Council 
of State and Territorial Epidemiologists recognized these 
benefits, and in 2003, recommended that past or present in-
fections with HCV (hereafter referred to as HCV infection 
because most of these cases likely represent chronic rather 
than acute or resolved HCV infections) become a nationally 
reportable condition. Surveillance for acute non-A, non-B 
hepatitis, which was mostly HCV infection, has been per-
formed in the United States since 1982, but in 2007, a total 
of 33 states also conducted surveillance for HCV infection 
and reported 133,520 cases to CDC; however, these data 
remain unpublished.
The Study
Our study had 2 objectives. The first objective was to 
describe findings from 6 US state or county health depart-
ments that have been funded by CDC to perform enhanced 
surveillance for HCV infection. The second objective was 
to  discuss  the  limitations  and  challenges  of  conducting 
population-based  surveillance  for  HCV  infection  in  the 
United States.
The sites where enhanced hepatitis surveillance was 
conducted during 2006–2007 were Colorado, Connecticut, 
Minnesota, New York (excluding New York City), and Or-
egon; Pinellas County, Florida, a sentinel counties (8) site, 
also contributed hepatitis C reports. The combined popula-
tion under surveillance from the 5 states and 1 county was 
an estimated 29.3 million in 2007 (Table). In each of these 
jurisdictions, clinical laboratories are required to report posi-
tive results from HCV assays. For this analysis, a confirmed 
case of HCV infection was identified in any person who, 
from July 1, 2006 through June 30, 2007, had at least 1 of 
the following: 1) a positive result for an HCV recombinant 
immunoblot assay (RIBA), 2) a positive nucleic acid test 
(NAT) result for HCV RNA, 3) a documented HCV geno-
type, or 4) a positive result for a screening test for antibodies 
against HCV (anti-HCV) with a signal-to-cutoff (s:co) ratio 
predictive of a true positive result for the given assay.
Laboratories and providers continuously reported posi-
tive results for HCV markers (e.g., anti-HCV, RIBA, NAT, 
genotype) to state or local health departments. Health de-
partment staff checked patients’ names and dates of birth 
from each report against a surveillance database to deter-
mine whether a case had been previously reported. Newly 
reported cases (i.e., previously not captured in the database 
of this jurisdiction) were entered into this database along 
with hepatitis test results. Health department staff investi-
gated cases and collected basic demographic and clinical 
information to confirm the case definition and to epidemio-
logically describe the case. We calculated rates of newly 
reported cases by using denominators available from the 
2007  population  estimates  from  the  US  Bureau  of  the   
Census (www.census.gov/compendia/statab).
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first assessment measured the number of laboratory re-
ports associated with each new case. Staff at each site 
monitored  a  convenience  sample  of  laboratory  reports 
and measured the number excluded, reasons for exclu-
sion, and the number that eventually were classified as 
newly reported cases. The second assessment determined 
the validity of basic epidemiologic information. For this 
task, CDC drew a random sample of 10 cases per site 
from among those reported during the 12-month reporting 
period (n = 60) and extracted the following variables: date 
of birth, county of residence, sex, race, and clinical test 
results associated with HCV infection. Surveillance staff 
contacted at least 1 healthcare provider to independently 
collect this information. We measured agreement between 
the information initially reported and the information col-
lected during the validation using a κ statistic (9).
The 6 sites reported a total of 20,285 cases of con-
firmed HCV infection that were previously unreported in 
their  respective  jurisdictions  (Table).  Of  these,  66%  of 
case-patients were male and 56% were 40–54 years of age 
(men and women combined) (Table). More than half (52%) 
of the reports lacked information on race or ethnicity. Most 
cases  (89%)  were  reported  by  clinical  laboratories.  The 
laboratory criterion most frequently reported was a posi-
tive result for HCV RNA (53%). The rate of new reports of 
past or present HCV infection was 69/100,000 population 
(range 25–108/100,000).
Sites monitored all incoming reports on average for 
8 days (range 5–16 days). A total of 2,180 reports were 
received and, among these, 491 (23%, range 13%–52%) 
met the case definition and were considered newly reported 
cases; Oregon had the highest proportion of newly reported 
cases (52%) and the newest registry. The remaining reports 
fell into the following categories: already in the database 
(68%, range 30%–78%), lacking value for s:co ratio (5%, 
range 3%–13%), negative test results for an HCV marker 
(2%,  range  1%–4%),  or  missing  key  demographic  data 
(1%, range 0%–2%).
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Table.	Newly	reported	cases	of	past	or	present	HCV	infection	in	6	US	locations,	July	1,	2006–June	30,	2007*†	
Characteristic Colorado Connecticut Minnesota New	York‡	 Oregon	
Pinellas
County,	
Florida Total 
Estimated	population,	2007	 4,862,000 3,502,000 5,198,000 11,068,000 3,747,000 924,000 29,301,000
Year registry initiated  1993 1994 1998 2003 2005 1999
Sex, no. (%)	
	 F	 1,088	(36.5)	 1,360	(35.9)	 494	(37.6)	 2,882	(30.4)	 711	(34.9)	 302	(45.4)	 6,837	(33.8)	
  M  1,879	(63.0)	 2,429	(64.1)	 804	(61.2)	 6,595 (69.5)	 1,285	(63.0)	 359	(54.0)	 13,351	(66.0)
	 Unknown	 16	(0.5)	 3	(0.1)	 15	(1.1)	 15	(0.2)	 44	(2.2)	 4	(0.6)	 53	(0.3)	
Age	group,	y,	no.	(%)	
	 0–14	 16	(0.5)	 9	(0.2)	 10	(0.8)	 14	(0.2)	 9	(0.4)	 5	(0.8)	 63	(0.3)	
	 15–24	 126	(4.2)	 127	(3.4)	 37	(2.8)	 318	(3.4)	 55	(2.7)	 25	(3.8)	 688	(3.4)	
	 25–39	 638	(21.4)	 741	(19.5)	 200	(15.2)	 1,527	(16.1)	 386	(18.9)	 69	(10.4)	 3,561	(17.6)	
	 40–54	 1,645	(55.2)	 2,158	(56.9)	 798	(60.8)	 5,153 (54.3)	 1,149	(56.3)	 411	(61.8)	 11,314	(56.0)
>55 546	(18.3)	 755	(19.9)	 267	(20.3)	 2,438	(25.7)	 422	(20.7)	 155	(23.3)	 4,583	(22.7)	
	 Unknown	 12	(0.4)	 2	(0.0)	 1	(0.1)	 42	(0.4)	 19	(0.9)	 0 76	(0.4)	
Case	criteria,	no.	(%)§	
	 Anti-HCV	and	supplemental		
  test 
593	(19.9)	 1,520	(40.1)	 520	(39.6)	 3,763	(39.6)	 203	(10.0)	 0 6,599	(32.5)	
	 RIBA	 527	(17.7)	 466	(12.3)	 384	(29.3)	 1,404	(14.8)	 185	(9.1)	 15	(2.3)	 2,981	(14.7)	
	 HCV	RNA	 1,245	(41.7)	 1,984	(52.3)	 928	(70.7)	 5,831	(61.4)	 818	(40.1)	 28	(4.2)	 10,834	(53.4)
	 Genotype	 586	(19.6)	 21	(0.6)	 304	(23.2)	 1,473 (15.5)	 207	(10.2)	 142	(21.4)	 2,733	(13.5)	
	 Anti-HCV	and	s:co	ratio	 1,859	(62.3)	 1,352	(35.7)	 253 (19.3)	 4,709	(49.6)	 905	(44.4)	 521	(78.4)	 9,599	(47.3)	
Source	of	report,	no.	(%)	
  Laboratory  2,561	(85.9)	 3,792	(100.0) 878	(66.9)	 8,252	(86.9)	 1,923	(94.3)	 592	(89.0)	 17,998	(88.7)
	 Others,	combined¶	 422	(14.2)	 0 435	(33.1)	 1,240	(13.1)	 117	(5.7)	 73	(11.0)	 2,287	(11.3)	
Total reports  2,983 3,792 1,313 9,492 2,040 665 20,285
Report	rate/100,000	population	 61.4 108.3 25.3 85.8 54.4 71.9 69.2
*HCV,	hepatitis	C	virus;	RIBA,		recombinant	immunoblot	assay;	anti-HCV,	antibodies	against	HCV;	s:co,	signal-to-cutoff.	
†A	confirmed	case	requires	laboratory	confirmation.	Laboratory	criteria consist of at least 1 of	the	following:	a	positive	result	for	a	HCV	RIBA,	a	positive	
result	for	a	nucleic	acid	test	for	HCV	RNA,	an	HCV	genotype,	or	enzyme	immunoassay	with	detection	of	anti-HCV	and	a	s:co	ratio	predictive	of	a	true	
positive	result	for	a	particular	assay	(see	www.cdc.gov/ncphi/disss/nndss/casedef/hepatitisccurrent.htm	for	the	2005	Council	of	State	and	Territorial	
Epidemiologists/Centers	for	Disease	Control	and	Prevention	case	definition).	
‡Excludes	New	York,	New	York.	
§Cases	could	be	reported	with	more	than	minimum	laboratory	criteria;	totals	add	up	to	>100%.	
¶Other	sources	of	reports	included	private	healthcare	providers,	facilities such as hospitals and outpatient clinics, and institutions such as prisons, blood 
banks, and drug treatment centers, among others. Surveillance	for	Hepatitis	C	Virus,	USA
All cases were confirmed to meet the case definition. 
Agreement was high for age (κ = 1.0, p<0.001), sex (κ = 
0.96; p<0.001), and county of residence (κ = 1.0; p<0.001); 
county data were missing for 6 (10%) cases.
Conclusions
We documented that for every 4 laboratory reports, 
≈1 newly reported case of HCV infection was identified. 
The overall annual rate of new case reports was 69/100,000 
population in 6 sites that were conducting enhanced sur-
veillance. In the 4 states (Colorado, Connecticut, Minne-
sota, Oregon) for which comparable data were available, 
the number of newly reported cases of HCV infection was 
at least 4× the number of newly reported HIV infections in 
2006 (10). The 1 county in Florida was not included in the 
comparison because no HIV data were available.
Two limitations must be mentioned. First, we do not 
know how many of the newly reported cases represent cur-
rent infections. In the United States, 80% of prevalent anti-
HCV–positive cases are HCV RNA positive (2); thus, most 
laboratory  confirmed  cases  reported  to  surveillance  are 
likely chronic infections, but could also represent acute or 
resolved infections. Electronic laboratory reporting is the 
most efficient way to identify potential cases (11), but be-
cause no current laboratory test can distinguish acute from 
chronic HCV infections, identification of acute-phase cases 
requires  contacting  the  provider  or  patient  to  determine 
whether acute symptoms were present. Due to the high vol-
ume of reports received, this level of follow-up was not 
routinely conducted.
The second major limitation is that testing patterns in 
the  community  are  unknown.  Providers  are  inconsistent 
about eliciting risk factor information and about testing and 
referring patients to specialists (12). Patient access to care 
and structural factors in institutions (e.g., incentives and 
disincentives for testing at jails, prisons, and drug treatment 
programs) and in the community (e.g., screenings) also af-
fect testing and, therefore, the reporting rate.
The  greatest  value  of  conducting  surveillance  for 
chronic HCV at the state and local level is to measure local 
frequency of disease. Local and state health departments 
share information such that changes of residence of cases 
within the state over time would not result in a duplicate 
case count. However, in aggregating these data at the na-
tional level, an infected person who moved from 1 state to 
another would likely trigger a new report in another state, 
thus resulting in an overestimate of the national prevalence. 
Therefore, as a coordinated surveillance system for chronic 
HCV is developed, a mechanism to prevent duplication of 
cases across states will need to be developed.
Many factors affect case reporting, such as, local pub-
lic health reporting requirements, the sophistication and ca-
pacity of laboratories to electronically report de-duplicated 
positive test results, availability of health department staff 
to conduct investigations and follow-up on reports, time 
since registry was initiated, and the capacity of the system 
to maintain ongoing surveillance efforts. Without an under-
standing of these factors, interpreting the meaning of new 
HCV infection case reports is difficult.
Local health departments need chronic HCV infection 
surveillance to document effects of disease, identify per-
sons in need of linkage to care, and prevent complications 
among  persons  infected  (13).  However,  accurately  col-
lecting the necessary information is challenging for health 
departments, and we currently lack evidence that obtain-
ing these data will result in a lower incidence of illness 
and death. A full assessment of the benefits and costs of 
conducting comprehensive surveillance for chronic HCV 
infection is overdue. Currently, the enhanced hepatitis sur-
veillance sites are developing recommendations for best 
practices and plan to share methods and tools with all in-
terested health departments. Future studies should evaluate 
what level of surveillance for chronic HCV is feasible and 
whether the prevention benefit is worth the effort.
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